These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 34509050)

  • 1. Development of a multiplex immuno-oncology biomarker and digital pathology workflow for assessment of urothelial carcinoma.
    Xie Y; Olkhov-Mitsel E; Alminawi S; Slodkowska E; Downes MR
    Pathol Res Pract; 2021 Oct; 226():153607. PubMed ID: 34509050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.
    Tretiakova M; Fulton R; Kocherginsky M; Long T; Ussakli C; Antic T; Gown A
    Mod Pathol; 2018 Apr; 31(4):623-632. PubMed ID: 29271413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Impact and Spatial Interplay of Immune Cells in Urothelial Cancer.
    Debatin NF; Bady E; Mandelkow T; Huang Z; Lurati MCJ; Raedler JB; Müller JH; Vettorazzi E; Plage H; Samtleben H; Klatte T; Hofbauer S; Elezkurtaj S; Furlano K; Weinberger S; Giacomo Bruch P; Horst D; Roßner F; Schallenberg S; Marx AH; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke TH; Hallmann S; Koch S; Adamini N; Lennartz M; Minner S; Simon R; Sauter G; Zecha H; Schlomm T; Blessin NC
    Eur Urol; 2024 Jul; 86(1):42-51. PubMed ID: 38383257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
    Davick JJ; Frierson HF; Smolkin M; Gru AA
    Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
    Vanguri RS; Smithy JW; Li Y; Zhuang M; Maher CA; Aleynick N; Peng X; Al-Ahmadie H; Funt SA; Rosenberg JE; Iyer G; Bajorin D; Mathews JC; Nadeem S; Panageas KS; Shen R; Callahan MK; Hollmann TJ
    J Pathol; 2023 Nov; 261(3):349-360. PubMed ID: 37667855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study.
    Taube JM; Roman K; Engle EL; Wang C; Ballesteros-Merino C; Jensen SM; McGuire J; Jiang M; Coltharp C; Remeniuk B; Wistuba I; Locke D; Parra ER; Fox BA; Rimm DL; Hoyt C
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34266881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments.
    Rüschoff J; Kumar G; Badve S; Jasani B; Krause E; Rioux-Leclercq N; Rojo F; Martini M; Cheng L; Tretiakova M; Mitchell C; Anders RA; Robert ME; Fahy D; Pyle M; Le Q; Yu L; Glass B; Baxi V; Babadjanova Z; Pratt J; Brutus S; Karasarides M; Hartmann A
    Virchows Arch; 2024 Apr; 484(4):597-608. PubMed ID: 38570364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiplex immunofluorescence staining and image analysis assay for diffuse large B cell lymphoma.
    Lee CW; Ren YJ; Marella M; Wang M; Hartke J; Couto SS
    J Immunol Methods; 2020 Mar; 478():112714. PubMed ID: 31783023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder.
    Eich ML; Chaux A; Guner G; Taheri D; Mendoza Rodriguez MA; Rodriguez Peña MDC; Baras AS; Hahn NM; Drake C; Sharma R; Bivalacqua TJ; Rezaei K; Netto GJ
    Hum Pathol; 2019 Jul; 89():24-32. PubMed ID: 31026471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal-subtype bladder tumours show a 'hot' immunophenotype.
    Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
    Histopathology; 2018 Nov; 73(5):748-757. PubMed ID: 29947424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Digital immunohistochemistry platform for the staining variation monitoring based on integration of image and statistical analyses with laboratory information system.
    Laurinaviciene A; Plancoulaine B; Baltrusaityte I; Meskauskas R; Besusparis J; Lesciute-Krilaviciene D; Raudeliunas D; Iqbal Y; Herlin P; Laurinavicius A
    Diagn Pathol; 2014; 9 Suppl 1(Suppl 1):S10. PubMed ID: 25565007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis.
    Loughrey MB; Bankhead P; Coleman HG; Hagan RS; Craig S; McCorry AMB; Gray RT; McQuaid S; Dunne PD; Hamilton PW; James JA; Salto-Tellez M
    Histopathology; 2018 Aug; 73(2):327-338. PubMed ID: 29575153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Fully Automated Artificial Intelligence System to Assist Pathologists' Diagnosis to Predict Histologically High-grade Urothelial Carcinoma from Digitized Urine Cytology Slides Using Deep Learning.
    Tsuji K; Kaneko M; Harada Y; Fujihara A; Ueno K; Nakanishi M; Konishi E; Takamatsu T; Horiguchi G; Teramukai S; Ito-Ihara T; Ukimura O
    Eur Urol Oncol; 2024 Apr; 7(2):258-265. PubMed ID: 38065702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. iPathology cockpit diagnostic station: validation according to College of American Pathologists Pathology and Laboratory Quality Center recommendation at the Hospital Trust and University of Verona.
    Brunelli M; Beccari S; Colombari R; Gobbo S; Giobelli L; Pellegrini A; Chilosi M; Lunardi M; Martignoni G; Scarpa A; Eccher A
    Diagn Pathol; 2014; 9 Suppl 1(Suppl 1):S12. PubMed ID: 25565219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
    Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B
    Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
    de Jong JJ; Stoop H; Nieboer D; Boormans JL; van Leenders GJLH
    Histopathology; 2018 Dec; 73(6):983-989. PubMed ID: 30003574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
    Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
    Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virtual multiplex immunohistochemistry: Application on cell block of effusion and aspiration cytology.
    Chan RCK; Li JJX; Yeung W; Chan AWH
    Diagn Cytopathol; 2020 May; 48(5):417-423. PubMed ID: 32017459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.
    Hodgson A; Slodkowska E; Jungbluth A; Liu SK; Vesprini D; Enepekides D; Higgins K; Katabi N; Xu B; Downes MR
    Am J Surg Pathol; 2018 Aug; 42(8):1059-1066. PubMed ID: 29750666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer.
    Jäntti T; Luhtala S; Mäenpää J; Staff S
    Tumour Biol; 2020 Nov; 42(11):1010428320971404. PubMed ID: 33169632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.